CA2660520A1 — Hepatitis c virus inhibitors
Assigned to Bristol Myers Squibb Holdings Ireland ULC · Expires 2008-02-21 · 18y expired
What this patent protects
The present disclosure relates to a compound of Formula (I), compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also di sclosed are pharmaceutical compositions containing such compounds and method s for using these compounds in the treatment of HCV i…
USPTO Abstract
The present disclosure relates to a compound of Formula (I), compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also di sclosed are pharmaceutical compositions containing such compounds and method s for using these compounds in the treatment of HCV infection.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.